Insider transactions

EDGAR

MiNK Therapeutics, Inc.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-22.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
9 transactions, 10,438 shares
Sum of shares × price per share: 119,884.19

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–39 of 39

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-12 Filed 2026-10-14Buell Jennifer Director · Officer: Chief Executive Officer
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)6,93810.56
73,265.28

Derived: shares × price per share. Exact value 73265.28.

74,195Direct (D) No
F2, F3
  • F2 Represents sales of shares, as a consequence of the vesting of restricted stock units, solely to satisfy tax withholding obligations incurred upon vesting.
  • F3 Represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.33 to $10.61. The reporting person undertakes to provide to the Company, any shareholder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Open filing 0001193125-26-421529 Read from the filing’s XML Dispute this row
2026-10-11 Filed 2026-10-14Buell Jennifer Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)23,191——81,133Direct (D) No
F1
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of MiNK Therapeutics, Inc. (the Company).
Open filing 0001193125-26-421529 Read from the filing’s XML Dispute this row
2026-10-11 Filed 2026-10-14Buell Jennifer Director · Officer: Chief Executive Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (23,191)
Disposed (D)23,1910.00
0

Derived: shares × price per share. Exact value 0.00.

46,382Direct (D) No
F1, F4
  • F1 Each restricted stock unit (RSU) represents a contingent right to receive one share of common stock of MiNK Therapeutics, Inc. (the Company).
  • F4 On October 11, 2023 the reporting person was granted RSUs under the Company's 2021 Equity Incentive Plan, vesting in three substantially equal annual installments on each of the third, fourth and fifth anniversaries of the grant date. This award was previously reported as covering 695,750 RSUs but was adjusted to 69,573 RSUs to reflect the 1-for-10 reverse stock split (rounding) that occurred on January 28, 2025.
Open filing 0001193125-26-421529 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-02Behner Peter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,48510.95
16,260.75

Derived: shares × price per share. Exact value 16260.75.

24,404Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-26-379522 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-02Ryan Barbara Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,62210.95
17,760.9

Derived: shares × price per share. Exact value 17760.90.

23,591Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-26-379518 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-02Corvese Brian Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,63310.95
17,881.35

Derived: shares × price per share. Exact value 17881.35.

54,770Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-26-379513 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-02WIINBERG ULF Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,27910.95
14,005.05

Derived: shares × price per share. Exact value 14005.05.

23,929Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-26-379575 Read from the filing’s XML Dispute this row
2026-09-01 Filed 2026-09-02Holcomb John Bradley Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,23310.95
13,501.35

Derived: shares × price per share. Exact value 13501.35.

4,691Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-26-379524 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Ryan Barbara Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)50012.6835
6,341.75

Derived: shares × price per share. Exact value 6341.7500.

22,969Direct (D) No
F1
  • F1 The reported transaction reflects the sale of Common Stock received by Ms. Ryan as compensation for services rendered as a member of the MiNK Therapeutic Inc.'s Board of Directors.
Open filing 0001193125-26-260084 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Ryan Barbara Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)1,00012.7995
12,799.5

Derived: shares × price per share. Exact value 12799.5000.

21,969Direct (D) No
F1
  • F1 The reported transaction reflects the sale of Common Stock received by Ms. Ryan as compensation for services rendered as a member of the MiNK Therapeutic Inc.'s Board of Directors.
Open filing 0001193125-26-260084 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-02Holcomb John Bradley Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,09112.38
13,506.58

Derived: shares × price per share. Exact value 13506.58.

3,458Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-26-253474 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-02Ryan Barbara Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,43412.38
17,752.92

Derived: shares × price per share. Exact value 17752.92.

23,469Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-26-253470 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-02Corvese Brian Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,44412.38
17,876.72

Derived: shares × price per share. Exact value 17876.72.

53,137Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-26-253468 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-02WIINBERG ULF Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,13112.38
14,001.78

Derived: shares × price per share. Exact value 14001.78.

22,650Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-26-253461 Read from the filing’s XML Dispute this row
2026-06-01 Filed 2026-06-02Behner Peter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,31312.38
16,254.94

Derived: shares × price per share. Exact value 16254.94.

22,919Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-26-253466 Read from the filing’s XML Dispute this row
2026-03-10 Filed 2026-03-11Ryan Barbara Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)30015.2822
4,584.66

Derived: shares × price per share. Exact value 4584.6600.

21,406Direct (D) No
F1
  • F1 The reported transaction reflects the sale of Common Stock received by Ms. Ryan as compensation for services rendered as a member of the MiNK Therapeutic Inc.'s Board of Directors.
Open filing 0001193125-26-102581 Read from the filing’s XML Dispute this row
2026-03-10 Filed 2026-03-11Ryan Barbara Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)50015.5652
7,782.6

Derived: shares × price per share. Exact value 7782.6000.

20,906Direct (D) No
F1
  • F1 The reported transaction reflects the sale of Common Stock received by Ms. Ryan as compensation for services rendered as a member of the MiNK Therapeutic Inc.'s Board of Directors.
Open filing 0001193125-26-102581 Read from the filing’s XML Dispute this row
2026-03-10 Filed 2026-03-11Ryan Barbara Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)50015.30
7,650

Derived: shares × price per share. Exact value 7650.00.

20,406Direct (D) No
F1
  • F1 The reported transaction reflects the sale of Common Stock received by Ms. Ryan as compensation for services rendered as a member of the MiNK Therapeutic Inc.'s Board of Directors.
Open filing 0001193125-26-102581 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-11Ryan Barbara Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)20010.1725
2,034.5

Derived: shares × price per share. Exact value 2034.5000.

21,706Direct (D) No
F1
  • F1 The reported transaction reflects the sale of Common Stock received by Ms. Ryan as compensation for services rendered as a member of the MiNK Therapeutic Inc.'s Board of Directors.
Open filing 0001193125-26-102581 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-06-02Holcomb John Bradley Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,23910.90
13,505.1

Derived: shares × price per share. Exact value 13505.10.

2,367Direct (D) No
F2
  • F2 Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.
Open filing 0001193125-26-253474 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-06-02Ryan Barbara Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,62910.90
17,756.1

Derived: shares × price per share. Exact value 17756.10.

22,035Direct (D) No
F2
  • F2 Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.
Open filing 0001193125-26-253470 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-06-02Corvese Brian Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,64010.90
17,876

Derived: shares × price per share. Exact value 17876.00.

51,693Direct (D) No
F2
  • F2 Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.
Open filing 0001193125-26-253468 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-06-02WIINBERG ULF Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,28510.90
14,006.5

Derived: shares × price per share. Exact value 14006.50.

21,519Direct (D) No
F3
  • F3 Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.
Open filing 0001193125-26-253461 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-06-02Behner Peter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,49110.90
16,251.9

Derived: shares × price per share. Exact value 16251.90.

21,606Direct (D) No
F2
  • F2 Due to an administrative error, the RSUs for Q1 2026 Board and committee compensation were not filed timely.
Open filing 0001193125-26-253466 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-04Ryan Barbara Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)10010.8258
1,082.58

Derived: shares × price per share. Exact value 1082.5800.

21,906Direct (D) No— Open filing 0001193125-26-091707 Read from the filing’s XML Dispute this row
2026-02-27 Filed 2026-03-04Ryan Barbara Director
S

Open market or private sale of non-derivative or derivative security

Common Stock
Disposed (D)40010.8583
4,343.32

Derived: shares × price per share. Exact value 4343.3200.

22,006Direct (D) No— Open filing 0001193125-26-091707 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-14Buell Jennifer Officer: Chief Executive Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)10,02411.12
111,466.88

Derived: shares × price per share. Exact value 111466.88.

57,942Direct (D) No
F1
  • F1 These shares were withheld for payment of the withholding taxes in relation to the stock issued to the reporting person on January 2, 2026, as previously reported on the Form 4 filed on January 6, 2026 (the Original Form 4). The Original Form 4 did not include the shares withheld for payment of withholding taxes in Table I. This amendment is being filed to correct this error.
Open filing 0001193125-26-012914 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Buell Jennifer Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)31,47411.12
349,990.88

Derived: shares × price per share. Exact value 349990.88.

67,966Direct (D) No
F1, F2
  • F1 Reflects the executive's 2025 performance bonus award paid in MiNK Therapeutics, Inc. common stock. The stock issued is fully-vested on the date of issuance but is subject to a lockup restriction with 100% of the award released on February 2, 2026.
  • F2 $11.12 was the fair market value of MiNK Therapeutics, Inc. Common Stock on January 2, 2026, the stock issuance date.
Open filing 0001193125-26-004799 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Buell Jennifer Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (50,000) — exercise price 11.12
Acquired (A)50,0000—50,000Direct (D) No
F3
  • F3 The option vests over a three-year period, with one-third of the options vesting on the one-year anniversary of the date of grant, with the remainder vesting in eight equal quarterly installments thereafter.
Open filing 0001193125-26-004799 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Corvese Brian Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (5,395) — exercise price 11.12
Acquired (A)5,3950.00
0

Derived: shares × price per share. Exact value 0.00.

5,395Direct (D) No
F1
  • F1 Option vests on February 2, 2026, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.
Open filing 0001193125-26-004776 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Behner Peter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (5,395) — exercise price 11.12
Acquired (A)5,3950—5,395Direct (D) No
F1
  • F1 Option vests on February 2, 2026, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.
Open filing 0001193125-26-004769 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06WIINBERG ULF Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (5,395) — exercise price 11.12
Acquired (A)5,3950.00
0

Derived: shares × price per share. Exact value 0.00.

5,395Direct (D) No
F1
  • F1 Option vests on February 2, 2026, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.
Open filing 0001193125-26-004786 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Ryan Barbara Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (5,395) — exercise price 11.12
Acquired (A)5,3950—5,395Direct (D) No
F1
  • F1 Option vests on February 2, 2026, provided that the Reporting Person continues to serve on the Issuer's Board of Directors through such date.
Open filing 0001193125-26-004779 Read from the filing’s XML Dispute this row
2025-12-01 Filed 2025-12-03Corvese Brian Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,61211.09
17,877.08

Derived: shares × price per share. Exact value 17877.08.

50,053Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-25-306681 Read from the filing’s XML Dispute this row
2025-12-01 Filed 2025-12-03Holcomb John Bradley Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,12811.09
12,509.52

Derived: shares × price per share. Exact value 12509.52.

1,128Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-25-306679 Read from the filing’s XML Dispute this row
2025-12-01 Filed 2025-12-03Ryan Barbara Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,60111.09
17,755.09

Derived: shares × price per share. Exact value 17755.09.

22,406Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-25-306678 Read from the filing’s XML Dispute this row
2025-12-01 Filed 2025-12-03Behner Peter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,46611.09
16,257.94

Derived: shares × price per share. Exact value 16257.94.

20,115Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-25-306680 Read from the filing’s XML Dispute this row
2025-12-01 Filed 2025-12-03Kadlec Robert Peter Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,21811.09
13,507.62

Derived: shares × price per share. Exact value 13507.62.

19,126Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-25-306676 Read from the filing’s XML Dispute this row
2025-12-01 Filed 2025-12-03WIINBERG ULF Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)1,26311.09
14,006.67

Derived: shares × price per share. Exact value 14006.67.

20,234Direct (D) No
F1
  • F1 The Reporting Person was granted restricted stock units (RSUs), which represent a contingent right to receive one share of Common Stock for each RSU. The RSUs were received in lieu of cash retainers for board and committee compensation. The RSUs will vest one month from the grant date.
Open filing 0001193125-25-306675 Read from the filing’s XML Dispute this row

Latest reported holdings

What each reporting owner last said they hold, as of the date shown. A transaction not yet filed is not in it.

Latest reported holdings
Reporting ownerSecurityShares owned afterDirect or indirectSource
Behner Peter DirectorStock Option (Right to Buy) Derivative security · underlying Common Stock5,395D As of 2026-01-02 Open filing 4
Behner Peter DirectorCommon Stock 24,404D As of 2026-09-01 Open filing 4
Buell Jennifer Director · Officer: Chief Executive OfficerRestricted Stock Units Derivative security · underlying Common Stock46,382D As of 2026-10-11 Open filing 4
Buell Jennifer Officer: Chief Executive OfficerStock Option (Right to Buy) Derivative security · underlying Common Stock50,000D As of 2026-01-02 Open filing 4
Buell Jennifer Director · Officer: Chief Executive OfficerCommon Stock 74,195D As of 2026-10-12 Open filing 4
Charette Austin Officer: Principal Accounting OfficerCommon Stock 40D As of 2026-03-23 Open filing 3
Corvese Brian DirectorStock Option (Right to Buy) Derivative security · underlying Common Stock5,395D As of 2026-01-02 Open filing 4
Corvese Brian DirectorCommon Stock 54,770D As of 2026-09-01 Open filing 4
Holcomb John Bradley DirectorStock Option (Right to Buy) Derivative security · underlying Common Stock4,174D As of 2025-09-23 Open filing 4
Holcomb John Bradley DirectorCommon Stock 4,691D As of 2026-09-01 Open filing 4
Kadlec Robert Peter DirectorStock Option (Right to Buy) Derivative security · underlying Common Stock3,225D As of 2025-09-09 Open filing 4
Kadlec Robert Peter DirectorCommon Stock 19,126D As of 2025-12-01 Open filing 4
Orilall Melissa Officer: Principal Financial OfficerCommon Stock 222I By spouseAs of 2026-04-09 Open filing 3
Ryan Barbara DirectorStock Option (Right to Buy) Derivative security · underlying Common Stock5,395D As of 2026-01-02 Open filing 4
Ryan Barbara DirectorCommon Stock 23,591D As of 2026-09-01 Open filing 4
WIINBERG ULF DirectorStock Option (Right to Buy) Derivative security · underlying Common Stock5,395D As of 2026-01-02 Open filing 4
WIINBERG ULF DirectorCommon Stock 27,830I See FootnoteAs of 2025-12-03 Open filing 4
WIINBERG ULF DirectorCommon Stock 27,830I See footnoteAs of 2026-09-02 Open filing 4
WIINBERG ULF DirectorCommon Stock 23,929D As of 2026-09-01 Open filing 4

Joint filers each report the same shares, so rows are not added together.

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.

Showing 1–26 of 26

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
VANGUARD CAPITAL MANAGEMENT LLC 68,452 SH859,073 dollarsLower by 208 Prior quarter: 68,660Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
DNB ASSET MANAGEMENT AS 43,960 SH551,698 dollarsLower by 11,182 Prior quarter: 55,142Open filing 0000912282-26-001448 Filed 2026-11-12 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager18,759 SH235,457 dollarsHigher by 3,186 Prior quarter: 15,573Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
Longbow Finance SA 16,667 SH209,171 dollarsUnchanged Prior quarter: 16,667Open filing 0001104659-26-126516 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 13,164 SH165,208 dollarsHigher by 4,877 Prior quarter: 8,287Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
BlackRock, Inc. Partly reported under another manager13,074 SH164,079 dollarsLower by 308 Prior quarter: 13,382Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
BOLTON SECURITIES CORPORATION 13,000 SH163,150 dollarsUnchanged Prior quarter: 13,000Open filing 0001457457-26-000016 Filed 2026-11-12 Dispute this row
Steward Partners Investment Advisory, LLC 2,000 SH25,100 dollarsUnchanged Prior quarter: 2,000Open filing 0001723397-26-000006 Filed 2026-11-13 Dispute this row
US BANCORP \DE\ Partly reported under another manager1,995 SH25,037 dollarsUnchanged Prior quarter: 1,995Open filing 0000036104-26-000059 Filed 2026-11-05 Dispute this row
UBS Group AG Partly reported under another manager1,462 SH18,348 dollarsLower by 3,423 Prior quarter: 4,885Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Federation des caisses Desjardins du Quebec Partly reported under another manager750 SH9,413 dollarsHigher by 250 Prior quarter: 500Open filing 0002022297-26-000010 Filed 2026-11-16 Dispute this row
Paladin Partners, LLC Partly reported under another manager500 SH6,275 dollarsLower by 500 Prior quarter: 1,000Open filing 0002141570-26-000006 Filed 2026-10-06 Dispute this row
Tower Research Capital LLC (TRC) Partly reported under another manager303 SH3,803 dollarsLower by 119 Prior quarter: 422Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row
Covestor Ltd 119 SH1 dollarsUnchanged Prior quarter: 119Open filing 0001909846-26-000012 Filed 2026-10-30 Dispute this row
MORGAN STANLEY Partly reported under another manager118 SH1,481 dollarsHigher by 5 Prior quarter: 113Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
OSAIC HOLDINGS, INC. Partly reported under another manager117 SH1,433 dollarsUnchanged Prior quarter: 117Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row
ROYAL BANK OF CANADA Partly reported under another manager72 SH1,000 dollarsNot in the prior quarter’s filings read Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row
WELLS FARGO COMPANY/MN Partly reported under another manager26 SH326 dollarsHigher by 24 Prior quarter: 2Open filing 0000072971-26-000342 Filed 2026-11-16 Dispute this row
Caitong International Asset Management Co., Ltd 18 SH226 dollarsUnchanged Prior quarter: 18Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 18 SH226 dollarsUnchanged Prior quarter: 18Open filing 0001085146-26-000940 Filed 2026-11-13 Dispute this row
Game Plan Financial Advisors, LLC 16 SH201 dollarsUnchanged Prior quarter: 16Open filing 0001802952-26-000004 Filed 2026-11-10 Dispute this row
Clearstead Advisors, LLC Partly reported under another manager14 SH176 dollarsUnchanged Prior quarter: 14Open filing 0000842775-26-000005 Filed 2026-11-06 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager13 SH163 dollarsUnchanged Prior quarter: 13Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager9 SH110 dollarsUnchanged Prior quarter: 9Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Key Financial Inc 4 SH50 dollarsUnchanged Prior quarter: 4Open filing 0001420506-26-002442 Filed 2026-11-02 Dispute this row
JONES FINANCIAL COMPANIES LLLP Partly reported under another manager1 SH12 dollarsUnchanged Prior quarter: 1Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • CITADEL ADVISORS LLC 15,440 SH
  • Big Sioux Wealth Management 812 SH
  • BARCLAYS PLC 24 SH
  • MERCER GLOBAL ADVISORS INC /ADV 23 SH
  • BFC Planning, Inc. 2 SH
  • LifeSteps Financial, Inc. 2 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text; they are read only when their rows add up to the totals the filer states.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Institutional ownership reported on Form 13F

13F filers report holding between 0.62% and 3.79% of shares outstanding.

Quarter ending 2026-09-30, against 5,133,645 shares on the cover dated 2026-11-06.

  • The lower figure counts positions a manager reports as its own with sole discretion. The upper figure counts every plain-share position and can count a share twice.
  • Neither includes holders that do not file Form 13F, or managers below the filing threshold.
Quarter-by-quarter 13F holders
QuarterManagers holdingShares, at leastShares, at mostFilings read
2026-09-30 2631,824194,6318,935
2026-06-30 3133,638218,2609,178
2026-03-31 2433,021139,9489,173
2025-12-31 2630,823166,2129,222
2025-09-30 1929,818104,3228,469
2025-06-30 2041,06261,9228,516
2025-03-31 1840,53162,9728,518
2024-12-31 24463,593809,4328,580

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read from their tags. Earlier schedules are free text: they are read only when every cover page states a share count and a percent, and the rest are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
GKCC, LLC Common Stock, par value $0.00001 per share11.794,640,000— Filed 2024-05-22SC 13GRead from the cover page textOpen filing 0001068238-24-000115 Dispute this row
Agenus Inc. (“Agenus”) Common Stock62.521,522,157— Filed 2023-05-26SC 13D/AAmendment 2Read from the cover page textOpen filing 0001193125-23-155541 Dispute this row
Agenus Inc. (“Agenus”) Common Stock6221,344,685— Filed 2023-05-03SC 13D/AAmendment 1Read from the cover page textOpen filing 0001193125-23-134576 Dispute this row
Garo H. Armen Common Stock, par value $0.00001 per share7.822,616,882— Filed 2022-02-14SC 13GRead from the cover page textOpen filing 0001193125-22-041640 Dispute this row
Agenus Inc. (“Agenus”) Common Stock79.826,332,958— Filed 2021-10-28SC 13DRead from the cover page textOpen filing 0001193125-21-311369 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

3,104,499 filings read, dated 1980-01-02 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
2015258,595
2016246,472
2017244,814
2018245,575
2019238,619
2020249,093
2021274,850
2022257,922
2023253,676
2024261,106
2025235,525
2026263,830

Filings made before the SEC required XML are listed, not extracted.

Back to MiNK Therapeutics, Inc.